Osteoporosis Drugs Market Trends Analysis and Growth Forecasts, 2025-2030 by Drug Class (Branded, Generics), Type (Bisphosphates, Parathyroid Hormone Therapy)

Dublin, May 22, 2025 (GLOBE NEWSWIRE) — The “Osteoporosis Drugs Market Size, Share, & Trends Analysis Report by Drug Class (Branded, Generics), Type (Bisphosphates, Parathyroid Hormone Therapy), Distribution Channel, Region, with Growth Forecasts, 2025-2030” has been added to ResearchAndMarkets.com’s offering.

The global Osteoporosis Drugs Market is poised for significant growth, with its valuation projected to amplify from USD 15.3 billion in 2024 to USD 18.8 billion by 2030, reflecting a steady CAGR of 3.50%. The surge in unhealthy lifestyle choices has led to an increased prevalence of osteoporosis, thereby driving demand in this market segment over the forecast period.

Patent expirations have catalyzed the urgency for generic alternatives of existing drugs, propelling growth in the osteoporosis generics sector. These dynamics are expected to open lucrative opportunities in the market.

Increasing awareness initiatives about osteoporosis care, driven by organizations like the National Osteoporosis Foundation, are expected to broaden market expansion. Such programs focus on awareness enhancement and professional training, significantly boosting market potential.

Osteoporosis Drugs Market Report Highlights

• In 2024, branded drugs dominated the market, mainly due to the high efficacy of bisphosphonates and rank ligand inhibitors for osteoporosis treatment.
• Generic drugs are anticipated to experience robust growth due to ongoing patent expiries and demand for affordable medication, particularly in emerging markets.
• North America held the largest market share in 2024, supported by the strong presence of established companies in the branded therapeutics sector.
• Asia-Pacific is forecasted to grow exponentially, driven by supportive governmental initiatives promoting osteoporosis care awareness.
• Leading market players are adopting sustainability strategies and expanding therapeutic portfolios for competitive advantage, exemplified by Actavis Inc.’s acquisition of Warner Chilcott PLC.

Why Should You Buy This Report?

• Comprehensive Market Analysis: Obtain detailed insights across major regions and segments.
• Competitive Landscape: Assess the market presence of key industry players.
• Future Trends: Identify pivotal market trends and growth drivers.
• Actionable Recommendations: Gain insights for discovering new revenue streams and formulating strategic decisions.

Key Attributes:

Companies Featured

• Amgen Inc.
• Eli Lilly and Company
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• GSK plc
• Radius Health, Inc.
• UCB S.A.
• Teva Pharmaceutical Industries Ltd.
• F. Hoffmann-La Roche Ltd

For more information about this report visit https://www.researchandmarkets.com/r/wfloej

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

• Osteoporosis Drugs Market